CBZ-CRCarbamazepine Controlled Release (medications)
Copyright 1988-2018 AcronymFinder.com, All rights reserved.
References in periodicals archive ?
Bial, a Portugal-based pharmaceutical company, has revealed positive results for a pivotal phase three non-inferiority study comparing the efficacy and safety of eslicarbazepine acetate (ESL) to controlled release carbamazepine (CBZ-CR) as monotherapy in newly diagnosed adult patients with partial-onset seizures, it was reported yesterday.
The phase three study was a randomised, double-blind, parallel-group, active-controlled and non-inferiority study, investigating the efficacy and safety of once-daily ESL (800 to 1600 mg/daily) as monotherapy treatment for newly diagnosed adults with partial-onset seizures in comparison with twice-daily CBZ-CR (400 to 1200 mg/daily).